Anlotinib Hydrochloride Capsules in Maintenance Treatment for Intermediate-High Risk Rhabdomyosarcoma in Children

NCT07137884 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

150

Enrollment

OTHER

Sponsor class

Conditions

Rhabdomyosarcoma Recurrent
Maintenance Treatment

Interventions

DRUG: Anlotinib+Cyclophosphamide+Vinorelbine
DRUG: Cyclophosphamide+Vinorelbine

Sponsor

Sun Yat-sen University